TGEN Tecogen Inc

Targeted Genetics Named One of Washington State's Fastest Growing Technology Companies in Deloitte Technology Fast 50 Program SEATTLE, Oct. 1 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (NASDAQ:TGEN) has been named to Deloitte's Technology Fast 50 Program for Washington State, a ranking of the 50 fastest growing technology companies in the area by Deloitte & Touche LLP. Rankings are based on the percentage of growth in fiscal year revenues over five years, from 1999-2003. The award was presented last evening in Seattle. "Targeted Genetics' commitment to product commercialization supports the Company's growth and success over the last several years. We are pleased that this progress has resulted in a fourth Deloitte & Touche Fast 50 award during the past five years," said H. Stewart Parker, president and chief executive officer of Targeted Genetics. "We continue to maintain our leadership position in the field of gene delivery with ongoing clinical programs targeting the treatment of cystic fibrosis and rheumatoid arthritis and the prevention of AIDS." The 2004 Washington State Technology Fast 50 list was developed by Deloitte & Touche based on an analysis of revenue growth from 1999 to 2003. Growth percentages were calculated and compared among technology companies in Washington State that met the Fast 50 eligibility criteria. Winners of the 19 regional Technology Fast 50 programs in the United States and Canada are automatically entered in the Deloitte Technology Fast 500 program, which ranks North America's top 500 fastest growing technology companies. For more information on the Fast 50 or Fast 500 programs, visit http://www.fast500.com/. Targeted Genetics develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies. For more information about the Company visit its website at http://www.targetedgenetics.com/. NOTE: This release contains forward-looking statements regarding our projected financial resources, intellectual property, clinical trials and regulatory filings and anticipated data from our clinical and preclinical programs. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from expectations for a number of reasons, including failure of our partners to provide funding, our failure to make progress with our clinical trials, our failure to obtain positive results from our preclinical programs, our failure to obtain or maintain regulatory approvals, our failure to maintain or protect our intellectual property and the other risks described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2004. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectation. DATASOURCE: Targeted Genetics Corporation CONTACT: Courtney Self of Targeted Genetics Corporation, +1-206-521-7392 Web site: http://www.fast500.com/ Web site: http://www.targetedgenetics.com/

Copyright